ABSTRACT
Mucormycosis is a rare but emerging fungal infection complicating solid organ transplantation (SOT), with a cumulative incidence of around 2% during the first year after SOT. The associated mortality rate is high, and surgical debridement is frequently required as part of the treatment along with antifungal therapy based mostly on amphotericin B formulations, We describe here an unusual case of hepatic mucormycosis in a liver transplant recipient that was successfully treated with clinical therapy based on liposomal amphotericin B followed by posaconazole, without surgical resection.
Subject(s)
Amphotericin B/administration & dosage , Antifungal Agents/administration & dosage , Liver Diseases/drug therapy , Liver Transplantation/adverse effects , Mucormycosis/drug therapy , Triazoles/administration & dosage , Drug Administration Schedule , Female , Humans , Immunosuppressive Agents/adverse effects , Liver Diseases/diagnosis , Liver Diseases/microbiology , Mucormycosis/diagnosis , Mucormycosis/microbiology , Time Factors , Treatment Outcome , Young AdultABSTRACT
This paper summarizes the 20 years of liver transplantation in Brazil, in the context of the Western world scenario. More than 5000 liver transplantations have been performed in the country since September 1, 1985. The living-donor liver transplantation, one of the landmarks in liver transplantation, was first described by our team in 1989. Brazil is the seventh country in number of liver transplants in the Western world and the first in Latin America. Almost 1000 procedures were performed in 2004, 19% of them involving living donors.
